Literature DB >> 25439775

Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage.

Carlo R Bartoli1, David J Restle2, David M Zhang2, Michael A Acker2, Pavan Atluri2.   

Abstract

OBJECTIVES: Bleeding is an important source of morbidity in patients with a left ventricular assist device. Evidence suggests a major role for von Willebrand factor. However, limited data exist to explain the mechanism(s) of von Willebrand factor degradation during left ventricular assist device support. We investigated whether left ventricular assist device-related shear stress and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13, the von Willebrand factor protease) altered von Willebrand factor metabolism.
METHODS: Whole blood was collected from patients (n = 8) with a left ventricular assist device. von Willebrand factor multimers and degradation fragments were characterized with electrophoresis and immunoblotting. To investigate mechanisms, an in vitro model was developed to generate the supraphysiologic shear stress of a continuous-flow left ventricular assist device. Normal human blood (n = 8) was cycled in a laboratory vortexer (∼2400 rpm, shear stress ∼175 dyne/cm(2), 4 hours) to reproduce the pathologic degradation of von Willebrand factor that occurs during left ventricular assist device support. To investigate the specific mechanistic roles of shear stress and ADAMTS-13 in von Willebrand factor degradation, purified von Willebrand factor protein ± ADAMTS-13 protease were exposed to supraphysiologic shear stress in the vortexer. von Willebrand factor multimers and 11 von Willebrand factor degradation fragments were characterized with electrophoresis and immunoblotting.
RESULTS: Left ventricular assist device support reduced large von Willebrand factor multimers and significantly increased 10/11 von Willebrand factor degradation fragments (P < .05). Normal human blood exposed to supraphysiologic shear stress in the vortexer demonstrated the same profile of von Willebrand factor degradation fragments as in a patient with a left ventricular assist device. Supraphysiologic shear stress alone caused modest mechanical demolition of large von Willebrand factor multimers into smaller multimers but did not greatly generate von Willebrand factor fragments. In the presence of supraphysiologic shear stress, ADAMTS-13 completely eliminated large von Willebrand factor multimers and generated statistically significant amounts of 11/11 von Willebrand factor degradation fragments (P < .05). The profile of von Willebrand factor fragments generated was identical to the profile that was observed in vivo in patients with a left ventricular assist device.
CONCLUSIONS: Supraphysiologic shear stress alone causes physical demolition of large von Willebrand factor multimers into smaller von Willebrand factor multimers. In the setting of supraphysiologic shear stress, ADAMTS-13 cleaves large von Willebrand factor multimers into von Willebrand factor degradation fragments. ADAMTS-13 may be a therapeutic target to reduce von Willebrand factor degradation and bleeding complications in patients with a left ventricular assist device.
Copyright © 2015 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25439775     DOI: 10.1016/j.jtcvs.2014.09.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  21 in total

Review 1.  Bleeding and thrombosis in chronic ventricular assist device therapy: focus on platelets.

Authors:  Antigone Koliopoulou; Stephen H McKellar; Matthew Rondina; Craig H Selzman
Journal:  Curr Opin Cardiol       Date:  2016-05       Impact factor: 2.161

2.  Reinventing the displacement left ventricular assist device in the continuous-flow era: TORVAD, the first toroidal-flow left ventricular assist device.

Authors:  Carlo R Bartoli; Jeffrey R Gohean; Richard W Smalling
Journal:  Ann Cardiothorac Surg       Date:  2021-03

3.  Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support.

Authors:  Lorenzo Valerio; Jawaad Sheriff; Phat L Tran; William Brengle; Alberto Redaelli; Gianfranco B Fiore; Federico Pappalardo; Danny Bluestein; Marvin J Slepian
Journal:  Thromb Res       Date:  2017-12-05       Impact factor: 3.944

4.  Pathologic von Willebrand factor degradation is a major contributor to left ventricular assist device-associated bleeding: pathophysiology and evolving clinical management.

Authors:  Carlo R Bartoli
Journal:  Ann Cardiothorac Surg       Date:  2021-05

5.  Left Ventricular Assist Devices in the Management of Heart Failure.

Authors:  Edo Y Birati; Mariell Jessup
Journal:  Card Fail Rev       Date:  2015-04

6.  A Continuum Model for the Unfolding of von Willebrand Factor.

Authors:  Mansur Zhussupbekov; Rodrigo Méndez Rojano; Wei-Tao Wu; Mehrdad Massoudi; James F Antaki
Journal:  Ann Biomed Eng       Date:  2021-08-16       Impact factor: 3.934

7.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

8.  Early signatures of bleeding and mortality in patients on left ventricular assist device support: novel methods for personalized risk-stratification.

Authors:  Tara Shrout; Travis Sexton; Olga Vsevolozhskaya; Maya Guglin; Alexis Shafii; Susan Smyth
Journal:  Biomarkers       Date:  2019-05-06       Impact factor: 2.658

Review 9.  Anticoagulation management in mechanical circulatory support.

Authors:  Sirtaz Adatya; Mosi K Bennett
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

10.  Development of malignancies and their outcomes in patients supported on continuous-flow left ventricular assist devices-a systematic review.

Authors:  Elizabeth J Maynes; Jonathan S Gordon; Matthew P Weber; Thomas J O'Malley; Tyler M Bauer; Chelsey T Wood; Rohinton J Morris; Louis E Samuels; John W Entwistle; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.